INGN · Inogen Inc

Track INGN — free

$5.41 +0.08 (+1.50%)

Russell 2000 member Rebalance outlook locked

Market Cap

$141.45M

26.54M

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 9 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 7, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

$354.30M

Trailing 12 months

Net income (TTM)

$20.90M

Trailing 12 months

Revenue growth YoY

+3.0%

Year over year

Operating margin

-8.7%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-3.5%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.3%

Year over year · more shares

Price change (1Y)

-33.3%

Trailing year

Short interest

5.4%

Latest settlement · 4.9 days to cover

View all 114 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol High

Market backdrop VIX 16.3 · calm Equity put/call 0.67

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −17%

below

Price vs 50-day avg −14%

below

RSI (14) 28

oversold

MACD trend Negative

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −23%

trailing

6-month return −14%

trailing

YTD return −21%

this year

Relative strength −27%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $6 › 200d $6 — 200d above 50d

Institutional flow Accumulating

+2% holders QoQ · +18 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

5.42% of float · ▲ +14.3% MoM · 4.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

129 holders — near 3-yr low, contrarian setup

Squeeze score 62

elevated · 0–100

Fundamentals

Strong

Revenue growth +4%

Y/Y

Gross margin 44%

contracting

EPS growth +43%

Y/Y

Free cash flow $-13.7M

Buyback $30.0K

authorized

Balance sheet $65.8M

net cash

Quant / Vol

risk profile

High

Volatility 42%

annualized · 1-yr

Max drawdown −40%

past year

ATR 3.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−17% Bearish

Price vs 50-day avg

−14% Bearish

RSI (14)

28 Neutral

MACD trend

Negative Bearish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $6 › 200d $6 — 200d above 50d

Institutional flow Accumulating

+2% holders QoQ · +18 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

5.42% of float · ▲ +14.3% MoM · 4.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

129 holders — near 3-yr low, contrarian setup

Price context

position in its 52-week range

Range low $5 Now $5 · 0% Range high $9

vs 200-day avg -17% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
INGN Inogen Inc this stock	$141.45M	-20.7%	+3.9%	—	5.4%
ABT Abbott Laboratories	$191.81B	-13.1%	+5.7%	30.9	1.2%
SYK Stryker Corp	$121.41B	-9.7%	+11.2%	32.8	1.8%
MDT Medtronic plc	$117.82B	-4.2%	+8.4%	24.7	1.1%
BSX Boston Scientific Corp	$70.00B	-49.6%	+12.5%	19.6	1.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

129

% held: 72.5%
Net QoQ: +267.7K sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

162

View

Short & Settlement

Short Interest Rising

Shares short

1.4M

Days to cover: 4.9d
Change: +180.1K sh

View

Short Volume

Short vol %

55%

As of: Sep 1, 2026

Short Total

View

Fails to Deliver

FTD shares

3.1K

Value: $18.6K
As of: Aug 11, 2026

View

Off-Exchange

Off-exchange %

31.1%

Week of: Jul 27, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$348.7M

Net income (FY): $22.7M
EPS diluted: $-0.86

View

Buybacks

Authorized

$30.0K

View

Filings

SEC Filings

Latest

10-Q

Filed: Aug 7, 2026
This year: 13

View

Proposed Sales

Value

$70.6K

Shares: 10.9K
Filed: Jul 1, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
INGN	-3.8%	-23.0%	-14.5%	-0.7%	-20.7%
SPY	-0.5%	-1.2%	+12.6%	-0.7%	+11.7%
vs SPY	-3.3%	-21.7%	-27.1%	-0.1%	-32.4%

Capital returns

Buyback program · as of Feb 28, 2026

Authorized

$30,000

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1294133 CUSIP 45780L104 13F (30d) 112 filings 112 filers Visit website Investor relations

INGN · Inogen Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance

Capital returns